An experimental blood test for pancreatic cancer is being evaluated by a commercial laboratory, an important milestone toward making the test available for patients.
Bio-Techne has a market capitalization of $11.65 billion. The Zacks Consensus Estimate for the company’s fiscal 2025 earnings indicates a 5.1% year-over-year increase on a 5.5% revenue improvement. In ...
Due to the limited efficacy of vaccines against SARS-CoV-2 and resistance to current therapies additional anti-viral therapeutics with pan-coronavirus activity are of high interest. Here ...
16, 2024 — New research has uncovered a potential unintended ... of batteries with high precision using only small amounts of current, which is expected to maximize the ...
Germline development is the development of the cell lineage that gives rise to the reproductive cells, called gametes, of sexually reproducing organisms. Primordial germ cells, the founder cells ...
As of 11:58:02 AM EST. Market Open. CENTENNIAL, CO / ACCESSWIRE / December 27, 2024 / NioCorp Developments Ltd. ("NioCorp" or the "Company") (NASDAQ:NB) will hold its 2024 Annual General Meeting ...
Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research ...